With crude and polypropylene costs rising after the Strait of Hormuz closure and fresh U.S. inflation data just ahead, many investors are rethinking how much risk they want to carry. Large cap defensive stocks can sometimes offer a middle ground by balancing exposure to inflation with the financial strength of bigger companies. This article looks at how the recent inflation shock and earnings season backdrop intersect with one U.S. Large-Cap Defensive Stocks screener and identifies 3 stocks that appear more directly exposed to the current news, helping you think about which kinds of defensive holdings may deserve closer attention right now.

Abbott Laboratories (ABT)

Overview: Abbott Laboratories is a global healthcare company that sells diagnostics, medical devices, generic pharmaceuticals, and nutritional products, covering everything from lab testing and diabetes monitoring to heart devices and infant formula.

Operations: Abbott generates most of its roughly US$45.1b in annual revenue from Medical Devices at US$22.0b, followed by Diagnostics at US$9.1b, Nutrition at US$8.3b, Established Pharmaceuticals at US$5.7b, and a small Other segment, with US revenue of about US$17.2b.

Market Cap: US$163.6b

Abbott Laboratories stands out in a period of rising crude costs and inflation worries because much of its revenue comes from essential products like diagnostics, diabetes care and cardiovascular devices, areas where demand often holds up even when budgets tighten. The stock combines this with a long dividend track record and expectations for earnings and revenue growth; however, the sharp earnings decline over the last year and margin compression show that resilience is not cost free. Inflation in logistics and commodities has already pressured profitability, and the balance sheet carries meaningful debt, so the company has little room for complacency as it integrates Exact Sciences and continues to invest in Libre and cancer diagnostics. Investors watching defensive healthcare leaders may want a closer look at how those trade offs stack up against its current valuation and inflation backdrop.

Abbott Laboratories appears to be a healthcare anchor stock, combining essential products, dividends and ongoing investment in Libre and cancer diagnostics. However, this stability may be masking a more complicated story. For a deeper look, start with the 5 key rewards and 2 important warning signs

ResMed (RMD)

Overview: ResMed is a healthcare technology company that makes devices and cloud software to diagnose, treat, and manage sleep apnea and other breathing disorders, as well as digital tools used by home health, hospice, and residential care providers.

Operations: ResMed generates most of its revenue from Sleep and Breathing Health at about US$4.9b, with Residential Care Software contributing roughly US$671m.

Market Cap: US$29.4b

ResMed gives you exposure to essential sleep and respiratory care at a time when inflation and freight costs are back in focus, yet demand for treatment often remains steady. The company combines a large Sleep and Breathing Health device business with high margin cloud tools like AirView, myAir, and Brightree, helping support earnings quality, strong net margins of 27.4%, and high ROE of 23.4%. At the same time, the MatrixCare sale, GLP 1 therapies, and potential pricing pressure from payers and competitors are real swing factors. If you are weighing how ResMed fits into a defensive healthcare allocation, the mix of reliable demand, digital growth ambitions, and these evolving risks deserves a closer look.

ResMed’s high margin cloud tools and strong net margins suggest a story that may be more than a sleep device play. See how the full picture looks in the analysis report for ResMed

Stryker (SYK)

Overview: Stryker is a medical technology company that supplies hospitals and surgeons with orthopedic implants, surgical tools, neurotechnology products, and digital platforms, from joint replacement and trauma hardware to stroke treatment devices and AI assisted virtual care systems.

Operations: Stryker generates about US$9.5b in revenue from Orthopaedics and roughly US$15.8b from MedSurg and Neurotechnology.

Market Cap: US$126.4b

Stryker provides exposure to essential surgical and hospital equipment at a time when investors are focusing on earnings resilience while inflation and input costs are back in view. The company combines a large portfolio of orthopedic implants and MedSurg products with growth areas such as Mako robotic assisted surgery and new tools like the TPX HD power system. It also faces pressure from higher debt, insider selling, and past inflation related supply chain costs for plastics, freight, and labor. For investors weighing Stryker against other defensive healthcare stocks, the mix of durable procedure demand, premium valuation, and these cost and balance sheet risks may be key factors to understand before deciding how it fits in a defensive allocation.

Stryker’s premium pricing and surgical demand story may be masking a sharper question about future pace. To see how expectations stack up against current pricing, start with the analyst forecasts for Stryker

The 3 stocks in this article are only a starting point, and the full U.S. Large-Cap Defensive Stocks screener surfaces 4 more large cap defensives with equally compelling stories around earnings quality, balance sheet strength, and inflation resilience. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter most to you, so you can focus on the highest conviction ideas in this defensive corner of the market.

Take Control of Your Investment Journey

If Stryker or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About Alternative Stock Paths?

Fresh opportunities can move quickly, and some entry points may appear before momentum becomes widely recognized. Before these ideas attract broader attention, consider exploring them.

• Look for potential turnaround stories with strong cash positions by scanning a curated list of solid balance sheet and fundamentals (47 results) that may be able to handle pressure while others are still adjusting.
• Explore structural themes in computing demand by focusing on 52 AI infrastructure stocks that is quietly supporting growth in this area while it may still be less widely followed.
• Review opportunities related to automation by examining 32 robotics and automation stocks involved in factories, logistics, and smart systems before expectations potentially change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.